XML 75 R58.htm IDEA: XBRL DOCUMENT
v3.25.0.1

Collaborative Arrangements and Licensing Agreements, Metagenomi (Details) - Metagenomi [Member] $ in Millions | 12 Months Ended
--- | ---
Dec. 31, 2022 USD ($) Target
Collaborative Arrangement and Licensing Agreement [Abstract] |
Number of targets to be researched, developed and commercialized | Target | 4
Number of additional targets to be researched, developed and commercialized | Target | 4
Payment to license technology | $ | $ 80
Research and development expense | $ | $ 80

X
- References No definition available. + Details
Name: | ions_CollaborativeArrangementAndLicensingAgreementAbstract
Namespace Prefix: | ions_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The number of additional targets to be researched, developed and commercialized under the collaboration agreement upon achievement of certain development milestones. + References No definition available. + Details
Name: | ions_NumberOfAdditionalTargetsToBeResearchedDevelopedAndCommercialized
Namespace Prefix: | ions_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition The number of targets to be researched, developed and commercialized under the collaboration agreement. + References No definition available. + Details
Name: | ions_NumberOfTargetsToBeResearchedDevelopedAndCommercialized
Namespace Prefix: | ions_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Amount of cash outflow to license technology under a collaboration and license agreement. + References No definition available. + Details
Name: | ions_PaymentToLicenseTechnology
Namespace Prefix: | ions_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of expense for research and development. Excludes cost for computer software product to be sold, leased, or otherwise marketed, writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both, and write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1 + Details
Name: | us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ions_MetagenomiLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |